Mdm2-mediated ubiquitylation: P53 and beyond

Cell Death and Differentiation

Volumn 17, Issue 1, 2010, Pages 93-102

  Marine, J C ^a   Lozano, G ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer therapy; MDM2; p53; ubiquitylation

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

CANCER THERAPY; COMPLEX FORMATION; DRUG TARGETING; FINGER; GENETICS; HUMAN; INTROSPECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; TUMOR; UBIQUITINATION; FEEDBACK SYSTEM; METABOLISM; NEOPLASM; PHYSIOLOGY;

FEEDBACK; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 77449101168     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2009.68     Document Type: Review

References (130)

1. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK et al. (2000) The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10: 429-439.
2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
3. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. (Pubitemid 27220766)
4. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS 420: 25-27. (Pubitemid 28037193)
5. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303. (Pubitemid 27220767)
6. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234. (Pubitemid 23156805)
7. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20: 4041-4049. (Pubitemid 32681609)
8. Ganguli G, Wasylyk B (2003) p53-independent functions of MDM2. Mol Cancer Res 1: 1027-1035. (Pubitemid 38044978)
9. Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107. (Pubitemid 29077858)
10. Michael D, Oren M (2003) The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Cancer Biol 13: 49-58.
11. Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res 1: 993-1000. (Pubitemid 38044974)
12. Levav-Cohen Y, Haupt S, Haupt Y (2004) Dynamics of the p53-Mdm2 feedback loop in individual cells. Growth Factors 23: 183-192.
13. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468. (Pubitemid 23073692)
14. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ (1993) The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90: 11623-11627. (Pubitemid 24008691)
15. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB et al. (2004) Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 36: 147-150. (Pubitemid 38174372)
16. Geva-Zatorsky N, Rosenfeld N, Itzkovitz S, Milo R, Sigal A, Dekel E et al. (2006) Oscillations and variability in the p53 system. Mol Syst Biol 2: 2006.0033.
17. Lahav G (2008) Oscillations by the p53-Mdm2 feedback loop. Adv Exp Med Biol 641: 28-38.
18. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1993) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 362: 857-860.
19. Thut CJ, Goodrich JA, Tjian R (1997) Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11: 1974-1986. (Pubitemid 27332984)
20. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE et al. (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776-26787. (Pubitemid 41040711)
21. White DE, Talbott KE, Arva NC, Bargonetti J (2006) Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res 66: 3463-3470.
22. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133: 612-626. (Pubitemid 351636297)
23. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83-97. (Pubitemid 38902816)
24. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
25. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
26. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G (1999) Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 188: 322-328. (Pubitemid 29317778)
27. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934.
28. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G (2006) Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 103: 3226-3231. (Pubitemid 43346452)
29. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G et al. (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232-3237. (Pubitemid 43346453)
30. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G (2006) Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26: 192-198.
31. Boesten LS, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EA et al. (2006) Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 13: 2089-2098. (Pubitemid 44742692)
32. Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E et al. (2007) Distinct roles of Mdm2 and Mdm4 in red cell production. Blood 109: 2630-2633. (Pubitemid 46425913)
33. Valentin-Vega YA, Okano H, Lozano G (2008) The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ 15: 1772-1781.
34. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10: 501-514. (Pubitemid 44854749)
35. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315. (Pubitemid 43163526)
36. Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J et al. (2004) Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 279: 36440-36444. (Pubitemid 39128984)
37. Yang W, Rozan LM, McDonald III ER, Navaraj A, Liu JJ, Matthew EM et al. (2007) CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 282: 3273-3281. (Pubitemid 47084358)
38. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T et al. (2007) Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 26: 113-122. (Pubitemid 46094704)
39. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M et al. (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9: 273-285.
40. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS et al. (2007) Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12: 355-366. (Pubitemid 47539309)
41. Minsky N, Oren M (2004) The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 16: 631-639. (Pubitemid 39531885)
42. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472.
43. Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G (2007) Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 27: 5479-5485. (Pubitemid 47124400)
44. Alt JR, Greiner TC, Cleveland JL, Eischen CM (2003) Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22: 1442-1450. (Pubitemid 36362707)
45. Mendrysa O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16-21. (Pubitemid 43042663)
46. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. (Pubitemid 39535748)
47. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R et al. (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15: 110-114. (Pubitemid 44921674)
48. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533. (Pubitemid 43927330)
49. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
50. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20: 8458-8467.
51. Lohrum MA, et Woods DB, Ludwig RL, Bálint E, Vousden KH (2001) C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21: 8521-8532. (Pubitemid 33108611)
52. Krummel KA, Lee CJ, Toledo F, Wahl GM (2005) The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 102: 10188-10193. (Pubitemid 41023347)
53. Bossis G, Ferrara P, Acquaviva C, Jariel-Encontre I, Piechaczyk M (2003) c-Fos protooncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol Cell Biol 23: 7425-7436. (Pubitemid 37211020)
54. Chen X, Chi Y, Bloecher A, Aebersold R, Clurman BE, Roberts JM (2004) N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol Cell 16: 839-847. (Pubitemid 39586541)
55. Argentini M, Barboule N, Wasylyk B (2001) The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20: 1267-1275. (Pubitemid 32269932)
56. Kawai H, Wiederschain D, Yuan ZM (2003) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 14: 4939-4947. (Pubitemid 36793339)
57. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH et al. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 14: 4929-4938. (Pubitemid 36793338)
58. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951. (Pubitemid 30180252)
59. Uldrijan S, Pannekoek WJ, Vousden KH (2007) An essential function of the extreme Cterminus of MDM2 can be provided by MDMX. EMBO J 26: 102-112. (Pubitemid 46094703)
60. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N et al. (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 26: 90-101. (Pubitemid 46094702)
61. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE (2006) Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 363: 433-450. (Pubitemid 44436256)
62. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18: 5690-5698. (Pubitemid 28450520)
63. Maki CG (1999) Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274: 16531-16535.
64. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL (2008) Structure of the MDM2/ MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15: 841-848. (Pubitemid 351524426)
65. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19: 94-102. (Pubitemid 30009229)
66. Hicke L, Dunn R (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19: 141-172. Review. (Pubitemid 37487346)
67. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W (2003) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972-1975. (Pubitemid 37523506)
68. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18: 1660-1672. (Pubitemid 29127078)
69. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21: 307-315. Review. (Pubitemid 43163526)
70. Carter S, Bischof O, Dejean A, Vousden KH (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9: 428-435. (Pubitemid 46511076)
71. Sasaki M, Nie L, Maki CG (2007) MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282: 14626-14634. (Pubitemid 47100428)
72. Nie L, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 2007; 282: 14616-14625. (Pubitemid 47100427)
73. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. (2003) Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342-344. (Pubitemid 36433728)
74. Sherr CJ (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673. (Pubitemid 44285999)
75. Marine JC, Dyer MA, Jochemsen AG (2007) MDMX: from bench to bedside. J Cell Sci 120: 371-378. Review. (Pubitemid 46332500)
76. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA (2007) The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12: 342-354. (Pubitemid 47539308)
77. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE et al. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53- dependent manner. Proc Natl Acad Sci USA 94: 6048-6053. (Pubitemid 27270633)
78. Rossi M, Demidov ON, Anderson CW, Appella E, Mazur SJ (2008) Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res 36: 7168-7180.
79. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O et al. (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15: 1067-1077. (Pubitemid 32417300)
80. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G et al. (2007) Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101: 269-278. (Pubitemid 46169880)
81. Batchelor E, Mock CS, Bhan I, Loewer A, Lahav G (2008) Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. Mol Cell 30: 277-289. (Pubitemid 351615316)
82. Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K et al. (2008) Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci USA 105: 4838-4843. (Pubitemid 351753833)
83. Meek DW, Knippschild U (2003) Posttranslational modification of MDM2. Mol Cancer Res 1: 1017-1026. Review. (Pubitemid 38044977)
84. Chiu SY, Asai N, Costantini F, Hsu W (2008) SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol 6: e310.
85. Roegiers F, Jan YN (2004) Asymmetric cell division. Curr Opin Cell Biol 16: 195-205. Review. (Pubitemid 38757296)
86. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M (1998) The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol 18: 3974-3982. (Pubitemid 28287921)
87. Yogosawa S, Miyauchi Y, Honda R, Tanaka H, Yasuda H (2003) Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem Biophys Res Commun 302: 869-872. (Pubitemid 36294056)
88. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G et al. (2008) NUMB controls p53 tumour suppressor activity. Nature 451: 76-80.
89. Sherley JL, Stadler PB, Johnson DR (1995) Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics. Proc Natl Acad Sci USA 92: 136-140.
90. Sui G, Affarel B, Shi Y, Brignone C, Wall NR, Yin P et al. (2004) Yin Yang 1 is a negative regulator of p53. Cell 117: 859-872. (Pubitemid 38798853)
91. Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R (2009) RYBP stabilizes p53 by modulating MDM2. EMBO Rep 10: 166-172.
92. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH et al. (1998) mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitinproteasome pathway. Cell Growth Differ 9: 79-84. (Pubitemid 28049530)
93. Honda R, Yasuda H (2000) Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19: 1473-1476. (Pubitemid 30171179)
94. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23: 1547-1556. (Pubitemid 38579515)
95. Clegg HV, Itahana K, Zhang Y (2008) Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 7: 287-292. (Pubitemid 351366489)
96. Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O et al. (2007) Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 9: 331-338. (Pubitemid 46344613)
97. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20-26. (Pubitemid 129495005)
98. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D et al. (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2- mediated degradation. Cancer Cell 5: 465-475. (Pubitemid 38610248)
99. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB et al. (2003) Physical and functional interactions between PML and MDM2. J Biol Chem 278: 29288-29297. (Pubitemid 36935845)
100. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP et al. (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6: 665-672. (Pubitemid 38960925)
101. Lindström MS, Deisenroth C, Zhang Y (2007) Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. Cell Cycle 6: 434-437. Review. (Pubitemid 46393446)
102. Horn HF, Vousden KH (2008) Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 27: 5774-5784.
103. Opferman JT, Zambetti GP (2006) Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death Differ 3: 898-901. Review.
104. Marine JC, Jochemsen AG (2005) Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun 331: 750-760. (Pubitemid 40615506)
105. Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7: 1-11.
106. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344. (Pubitemid 351717524)
107. Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M et al. (1999) A novel cofactor for p300 that regulates the p53 response. Mol Cell 4: 365-376. (Pubitemid 29499789)
108. Coutts AS, Boulahbel H, Graham A, La Thangue NB (2007) Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep 8: 84-90. (Pubitemid 46043805)
109. Moumen A, Masterson P, O'Connor MJ, Jackson SP (2005) hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123: 1065-1078. (Pubitemid 41785421)
110. Boesten LS, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EA et al. (2006) Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 13: 2089-2098. (Pubitemid 44742692)
111. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
112. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. (2007) MDM2- regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damageinduced apoptosis. Mol Cell 25: 739-750. (Pubitemid 46341925)
113. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148. (Pubitemid 351194043)
114. Maguire M, Nield PC, Devling T, Jenkins RE, Park BK, Polañski R et al. (2008) MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res 68: 3232-3242.
115. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987. Review.
116. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
117. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G (2007) High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38: 1553-1562. (Pubitemid 47418967)
118. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799. (Pubitemid 24068339)
119. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T et al. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of Bcell origin. Blood 84: 3158-3165.
120. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95: 15608-15612. (Pubitemid 29018747)
121. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR et al. (1997) Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11: 714-725. (Pubitemid 27157160)
122. Bouska A, Lushnikova T, Plaza S, Eischen CM (2008) Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 28: 4862-4874.
123. Froment P, Dupont J, Christophe-Marine J (2008) Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 7: 3098-3103.
124. Girnita L, Girnita A, Larsson O (2003) Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 100: 8247-8252. (Pubitemid 36842530)
125. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334. (Pubitemid 44960417)
126. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665. (Pubitemid 46232887)
127. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660. (Pubitemid 46232886)
128. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328. (Pubitemid 40022713)
129. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. (Pubitemid 38174664)
130. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559. (Pubitemid 40799248)